{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:20:04Z","timestamp":1785284404888,"version":"3.55.0"},"reference-count":35,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["800176"],"award-info":[{"award-number":["800176"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,9,4]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This article describes the protocol of an Ebola vaccine clinical trial which investigates the safety and immunogenicity of a two-dose prophylactic Ebola vaccine regimen comprised of two Ebola vaccines (Ad26.ZEBOV and MVA-BN-Filo) administered 56 days apart, followed by a booster vaccination with Ad26.ZEBOV offered at either 1\u2009year or 2 years (randomisation 1:1) after the first dose. This clinical trial is part of the EBOVAC3 project (an Innovative Medicines Initiative 2 Joint Undertaking), and is the first to evaluate the safety and immunogenicity of two different booster vaccination arms in a large cohort of adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This study is an open-label, monocentric, phase 2, randomised vaccine trial. A total of 700 healthcare providers and frontliners are planned to be recruited from the Tshuapa province in the Democratic Republic of the Congo (DRC). The primary and secondary objectives of the study assess the immunogenicity of the first (Ad26.ZEBOV), second (MVA-BN-Filo) and booster (Ad26.ZEBOV) dose. Immunogenicity is assessed through the evaluation of EBOV glycoprotein binding antibody responses after vaccination. Safety is assessed through the collection of serious adverse events from the first dose until 6 months post booster vaccination and the collection of solicited and unsolicited adverse events for 1\u2009week after the booster dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol was approved by the National Ethics Committee of the Ministry of Health of the DRC (n\u00b0121\/CNES\/BN\/PMMF\/2019). The clinical trial was registered on 4 December 2019 on ClinicalTrials.gov. Trial activities are planned to finish in October 2022. All participants are required to provide written informed consent and no study-related procedures will be performed until consent is obtained. The results of the trial will be added on ClinicalTrials.gov, published in peer-reviewed journals and presented at international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT04186000\">NCT04186000<\/jats:ext-link>\n                      ; Pre-results.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-046835","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:46:20Z","timestamp":1632876380000},"page":"e046835","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04186000","registry":"10.18810\/clinical-trials-gov","type":"preResults"},{"clinical-trial-number":"nct02325050","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02564523","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02509494","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02325050","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02564523","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02509494","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02564523","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02509494","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5422-0194","authenticated-orcid":false,"given":"Ynke","family":"Larivi\u00e8re","sequence":"first","affiliation":[{"name":"Centre for Evaluation of Vaccination, University of Antwerp, Wilrijk, Belgium"},{"name":"Global Health Institute, University of Antwerp, Wilrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tr\u00e9sor","family":"Zola","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Stoppie","sequence":"additional","affiliation":[{"name":"Centre for Evaluation of Vaccination, University of Antwerp, Wilrijk, Belgium"},{"name":"Global Health Institute, University of Antwerp, Wilrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivi","family":"Maketa","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junior","family":"Matangila","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mitashi","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"De Bie","sequence":"additional","affiliation":[{"name":"Centre for Evaluation of Vaccination, University of Antwerp, Wilrijk, Belgium"},{"name":"Global Health Institute, University of Antwerp, Wilrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hypolite","family":"Muhindo-Mavoko","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Van geertruyden","sequence":"additional","affiliation":[{"name":"Global Health Institute, University of Antwerp, Wilrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Van Damme","sequence":"additional","affiliation":[{"name":"Centre for Evaluation of Vaccination, University of Antwerp, Wilrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"2025120520094728000_11.9.e046835.1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-052016-100506"},{"key":"2025120520094728000_11.9.e046835.2","doi-asserted-by":"publisher","DOI":"10.4102\/ojvr.v79i2.451"},{"key":"2025120520094728000_11.9.e046835.3","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.aogh.2015.02.005","article-title":"Transmission of ebola virus disease: an overview","volume":"80","author":"Rewar","year":"2014","journal-title":"Ann Glob Health"},{"key":"2025120520094728000_11.9.e046835.4","doi-asserted-by":"publisher","DOI":"10.3201\/eid1102.040533"},{"key":"2025120520094728000_11.9.e046835.5","unstructured":"World Health Organization . Ebola virus disease. Fact sheet N 103, 2014."},{"key":"2025120520094728000_11.9.e046835.6","doi-asserted-by":"publisher","DOI":"10.4306\/pi.2012.9.1.17"},{"key":"2025120520094728000_11.9.e046835.7","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"The Lancet"},{"key":"2025120520094728000_11.9.e046835.8","unstructured":"World health Organization . Ebola - North Kivu, Democratic Republic of the Congo, 2021, 2021. Available: https:\/\/www.who.int\/emergencies\/situations\/ebola-2021-north-kivu"},{"key":"2025120520094728000_11.9.e046835.9","unstructured":"International Committee on Taxonomy . Virus metadata Repository: version may 1, 2020; MSL35, 2020."},{"key":"2025120520094728000_11.9.e046835.10","unstructured":"World Health Organization . Situation report Ebola virus disease. Available: http:\/\/apps.who.int\/ebola\/ebola-situation-reports [Accessed 10 Jun 2016]."},{"key":"2025120520094728000_11.9.e046835.11","unstructured":"Ebovac . EBOVAC3, 2020. Available: https:\/\/www.ebovac.org\/ebovac-3\/"},{"key":"2025120520094728000_11.9.e046835.12","unstructured":"European Commission . Vaccine against Ebola: Commission grants new market authorisation, 2020. Available: https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_20_1248"},{"key":"2025120520094728000_11.9.e046835.13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and immunogenicity of a 2-Dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania","volume":"220","author":"Anywaine","year":"2019","journal-title":"J Infect Dis"},{"key":"2025120520094728000_11.9.e046835.14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4218"},{"key":"2025120520094728000_11.9.e046835.15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and immunogenicity of a 2-Dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya","volume":"220","author":"Mutua","year":"2019","journal-title":"J Infect Dis"},{"key":"2025120520094728000_11.9.e046835.16","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1264755"},{"key":"2025120520094728000_11.9.e046835.17","unstructured":"Safety and immunogenicity of a two-dose heterologous Ad26 . ZEBOV and MVA-BN\u00ae-Filo Ebola vaccine regimen: a phase 2 randomised clinical study in Europe (EBOVAC2. Amsterdam, Netherlands: 29th ECCMID, 2019."},{"key":"2025120520094728000_11.9.e046835.18","doi-asserted-by":"crossref","unstructured":"Goldstein N , Bockstal V , Bart S . Safety and immunogenicity of heterologous and homologous 2-Dose regimens of adenovirus serotype 26\u2013 and modified vaccinia Ankara\u2013Vectored Ebola vaccines: a randomized, controlled phase 1 study. J Infect Dis 2020;4.doi:10.1093\/infdis\/jiaa586","DOI":"10.1093\/infdis\/jiaa586"},{"key":"2025120520094728000_11.9.e046835.19","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1016\/S2214-109X(15)00065-0","article-title":"Health-care worker mortality and the legacy of the Ebola epidemic","volume":"3","author":"Evans","year":"2015","journal-title":"Lancet Glob Health"},{"key":"2025120520094728000_11.9.e046835.20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/infdis\/jiy499","article-title":"Serologic markers for ebolavirus among healthcare workers in the Democratic Republic of the Congo","volume":"219","author":"Hoff","year":"2019","journal-title":"J Infect Dis"},{"key":"2025120520094728000_11.9.e046835.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411099"},{"key":"2025120520094728000_11.9.e046835.22","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3201\/eid2209.160354","article-title":"Ebola virus disease, Democratic Republic of the Congo, 2014","volume":"22","author":"Nanclares","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2025120520094728000_11.9.e046835.23","first-page":"661","article-title":"Meeting of the strategic Advisory group of experts on immunization, October 2018\u2013Conclusions and recommendations.","volume":"93","year":"2018","journal-title":"Weekly Epidemiological Record"},{"key":"2025120520094728000_11.9.e046835.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.11.004"},{"key":"2025120520094728000_11.9.e046835.25","unstructured":"Vaccines J , Prevention BV . Investigator\u2019s Brochure VAC52150 (Ad26.ZEBOV, MVA-BN-Filo [MVA-mBN226B. 1 ed, 2020: 1\u2013163."},{"key":"2025120520094728000_11.9.e046835.26","unstructured":"Kabacoff RI . Power analysis, 2017. Available: https:\/\/www.statmethods.net\/stats\/power.html"},{"key":"2025120520094728000_11.9.e046835.27","doi-asserted-by":"crossref","DOI":"10.2196\/28573","article-title":"Use of iris scanning for biometric recognition of healthy adults participating in an Ebola vaccine trial in the Democratic Republic of the Congo: mixed methods study","volume":"23","author":"Zola Matuvanga","year":"2021","journal-title":"J Med Internet Res"},{"key":"2025120520094728000_11.9.e046835.28","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3201\/eid2609.191552","article-title":"Role of wildlife in emergence of Ebola virus in Kaigbono (Likati), Democratic Republic of the Congo, 2017","volume":"26","author":"Gryseels","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2025120520094728000_11.9.e046835.29","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404792"},{"key":"2025120520094728000_11.9.e046835.30","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-100616-060718"},{"key":"2025120520094728000_11.9.e046835.31","unstructured":"UNICEF . Deuxi\u00e8me enqu\u00eate d\u00e9mographique et de sant\u00e9 (EDS-RDC II 2013-2014, 2014."},{"key":"2025120520094728000_11.9.e046835.32","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130254"},{"key":"2025120520094728000_11.9.e046835.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2018.08.008"},{"key":"2025120520094728000_11.9.e046835.34","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.171085"},{"key":"2025120520094728000_11.9.e046835.35","unstructured":"d-maps.com . cartographer Map DR of the Congo: boundaries, provinces. Available: https:\/\/d-maps.com\/carte.php?num_car=4886&lang=en2020"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-046835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:09:59Z","timestamp":1764994199000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-046835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,28]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bmjopen-2020-046835"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-046835","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}